Skip to main content

Table 2 Anti-tumor effect of nivolumab in previously treated malignant pleural mesothelioma patients

From: Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma

No. of patients 11  
Best overall response (%)
 CR 0 (0.0)
 PR 2 (18.2)
 SD 8 (72.7)
 PD 1 (9.1)
ORR 18.2%  
DCR 90.9%  
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, DCR disease control rate